Genetic polymorphisms of diabetes-related genes, their interaction with diabetes status, and breast cancer incidence and mortality: The Long Island Breast Cancer Study Project.
Adult
Aged
Aged, 80 and over
Biomarkers
/ analysis
Breast Neoplasms
/ epidemiology
Case-Control Studies
Diabetes Mellitus
/ genetics
Female
Follow-Up Studies
Genetic Predisposition to Disease
Genome-Wide Association Study
Genotype
Humans
Incidence
Middle Aged
Polymorphism, Single Nucleotide
Prognosis
Survival Rate
Young Adult
breast cancer
diabetes
genetics
incidence
mortality
single nucleotide polymorphisms
survival
Journal
Molecular carcinogenesis
ISSN: 1098-2744
Titre abrégé: Mol Carcinog
Pays: United States
ID NLM: 8811105
Informations de publication
Date de publication:
03 2019
03 2019
Historique:
received:
02
08
2018
revised:
01
11
2018
accepted:
09
11
2018
pubmed:
21
11
2018
medline:
10
7
2019
entrez:
21
11
2018
Statut:
ppublish
Résumé
To examine 143 diabetes risk single nucleotide polymorphisms (SNPs), identified from genome-wide association studies, in association with breast cancer (BC) incidence and subsequent mortality. A population-based sample of Caucasian women with first primary invasive BC (n = 817) and controls (n = 1021) were interviewed to assess diabetes status. Using the National Death Index, women with BC were followed for >18 years during which 340 deaths occurred (139 BC deaths). Genotyping was done using DNA extracted from blood samples. We used unconditional logistic regression to estimate age-adjusted odds ratios and 95% confidence intervals (CIs) for BC incidence, and Cox regression to estimate age-adjusted hazard ratios and CIs for all-cause and BC-specific mortality. Twelve SNPs were associated with BC risk in additive genotype models, at α = 0.05. The top three significant SNPs included SLC30A8-rs4876369 (P = 0.0034), HHEX-rs11187146 (P = 0.0086), and CDKN2A/CDKN2B-rs1333049 (P = 0.0094). Diabetes status modified the associations between rs4876369 and rs2241745 and BC incidence, on the multiplicative interaction scale. Six SNPs were associated with all-cause (CDKAL1-rs981042, P = 0.0032; HHEX-rs1111875, P = 0.0361; and INSR-rs919275, P = 0.0488) or BC-specific (CDKN2A/CDKN2B-rs3218020, P = 0.0225; CDKAL1-rs981042, P = 0.0246; and TCF2/HNF1B-rs3094508, P = 0.0344) mortality in additive genotype models, at α = 0.05. Genetic polymorphisms that increase the risk of developing diabetes may also increase the risk of developing and dying from BC.
Identifiants
pubmed: 30457165
doi: 10.1002/mc.22940
pmc: PMC6377588
mid: NIHMS1011776
doi:
Substances chimiques
Biomarkers
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
436-446Subventions
Organisme : Susan G. Komen Foundation (Career Catalyst Award)
Pays : International
Organisme : NIEHS NIH HHS
ID : T32 ES007018
Pays : United States
Organisme : NCI NIH HHS
ID : UO1 CA66572
Pays : United States
Organisme : NCI NIH HHS
ID : UO1 CA/ES66572
Pays : United States
Organisme : NIEHS NIH HHS
ID : P30 ES009089
Pays : United States
Organisme : NCI NIH HHS
ID : L30 CA220767
Pays : United States
Organisme : NCI NIH HHS
ID : U01 CA066572
Pays : United States
Informations de copyright
© 2018 Wiley Periodicals, Inc.
Références
Int J Epidemiol. 2004 Feb;33(1):30-42
pubmed: 15075143
Nature. 2016 Aug 4;536(7614):41-47
pubmed: 27398621
Med Care. 2005 Feb;43(2):132-40
pubmed: 15655426
Bioinformatics. 2008 Dec 15;24(24):2938-9
pubmed: 18974171
Diabetes Metab Res Rev. 2009 Jan;25(1):41-9
pubmed: 19145584
Endocr Relat Cancer. 2009 Dec;16(4):1103-23
pubmed: 19620249
Clin Psychopharmacol Neurosci. 2017 Feb 28;15(1):53-58
pubmed: 28138111
Int J Cancer. 2016 Feb 1;138(3):565-75
pubmed: 26285160
Trends Endocrinol Metab. 2015 Apr;26(4):176-84
pubmed: 25744911
Diabetologia. 2011 Aug;54(8):2038-46
pubmed: 21573907
Int J Cancer. 2007 Aug 15;121(4):856-62
pubmed: 17397032
J Biomed Res. 2014 Jan;28(1):53-8
pubmed: 24474964
Nat Genet. 2008 May;40(5):638-45
pubmed: 18372903
PLoS One. 2015 Feb 13;10(2):e0117419
pubmed: 25679392
CA Cancer J Clin. 2018 Jan;68(1):7-30
pubmed: 29313949
Diabetologia. 1997 Jul;40 Suppl 2:S25-31
pubmed: 9248698
Diabetes. 2005 Dec;54 Suppl 2:S40-5
pubmed: 16306339
BMJ. 2000 Sep 9;321(7261):624-8
pubmed: 10977847
Clin Endocrinol (Oxf). 2013 Mar;78(3):321-9
pubmed: 23121642
J Cell Physiol. 1988 Jan;134(1):101-8
pubmed: 3275677
Cancer Causes Control. 2016 May;27(5):679-93
pubmed: 27053251
Cancer Epidemiol Biomarkers Prev. 2011 May;20(5):1039-42
pubmed: 21357383
Science. 2007 Jun 1;316(5829):1331-6
pubmed: 17463246
Breast Cancer Res Treat. 2002 Jun;74(3):235-54
pubmed: 12206514
Diabetes Care. 2010 Jul;33(7):1674-85
pubmed: 20587728
Int J Cancer. 2007 May 1;120(9):1986-92
pubmed: 17230509
Curr Opin Clin Nutr Metab Care. 2008 Jul;11(4):371-7
pubmed: 18541994
JAMA. 2008 Dec 17;300(23):2754-64
pubmed: 19088353
Breast Cancer Res Treat. 2005 Jun;91(3):243-8
pubmed: 15952057
Cancer Epidemiol Biomarkers Prev. 2012 Mar;21(3):552-6
pubmed: 22237986
Mol Endocrinol. 1992 Dec;6(12):2219-28
pubmed: 1283442
PLoS One. 2017 Jan 10;12(1):e0169781
pubmed: 28072873
Cancer Causes Control. 2012 Jul;23(7):1193-203
pubmed: 22674293
Diabetes Care. 2003 Apr;26(4):1047-51
pubmed: 12663571
Nat Rev Genet. 2002 May;3(5):391-7
pubmed: 11988764
J Clin Oncol. 2011 Jan 1;29(1):40-6
pubmed: 21115865